Temporal supersampling for foveated rendering systems

Methods and systems are provided for using temporal supersampling to increase a displayed resolution associated with peripheral region of a foveated rendering view. A method for enabling reconstitution of higher resolution pixels from a low resolution sampling region for fragment data is provided. The method includes an operation for receiving a fragment from a rasterizer of a GPU and for applying temporal supersampling to the fragment with the low resolution sampling region over a plurality of prior frames to obtain a plurality of color values. The method further includes an operation for reconstituting a plurality of high resolution pixels in a buffer that is based on the plurality of color values obtained via the temporal supersampling. Moreover, the method includes an operation for sending the plurality of high resolution pixels for display.

Foveal adaptation of particles and simulation models in a foveated rendering system

A method for implementing a graphics pipeline. The method includes generating a system of particles creating an effect in a virtual scene, the system of particles comprising a plurality of particle geometries. The method includes determining a subsystem of particles from the system of particles, the subsystem of particles comprising a subset of particle geometries taken from the plurality of particle geometries. The method includes determining a foveal region when rendering an image of the virtual scene, wherein the foveal region corresponds to where an attention of a user is directed. The method includes determining that at least one portion of the effect is located in the peripheral region for the image. The method includes rendering the subsystem of particles to generate the effect.

Optimized deferred lighting in a foveated rendering system

A method for implementing a graphics pipeline. The method includes determining a plurality of light sources affecting a virtual scene. Geometries of objects of an image of the scene is projected onto a plurality of pixels of a display from a first point-of-view. The pixels are partitioned into a plurality of tiles. A foveal region of highest resolution is defined for the image as displayed, wherein a first subset of pixels is assigned to the foveal region, and wherein a second subset of pixels is assigned to a peripheral region that is outside of the foveal region. A first set of light sources is determined from the plurality of light sources that affect one or more objects displayed in a first tile that is in the peripheral region. At least two light sources from the first set is clustered into a first aggregated light source affecting the first tile when rendering the image in pixels of the first tile.

Optimized deferred lighting in a foveated rendering system

A method for implementing a graphics pipeline. The method includes determining a plurality of light sources affecting a virtual scene. Geometries of objects of an image of the scene is projected onto a plurality of pixels of a display from a first point-of-view. The pixels are partitioned into a plurality of tiles. A foveal region of highest resolution is defined for the image as displayed, wherein a first subset of pixels is assigned to the foveal region, and wherein a second subset of pixels is assigned to a peripheral region that is outside of the foveal region. A first set of light sources is determined from the plurality of light sources that affect one or more objects displayed in a first tile that is in the peripheral region. At least two light sources from the first set is clustered into a first aggregated light source affecting the first tile when rendering the image in pixels of the first tile.

TEMPORAL SUPERSAMPLING FOR FOVEATED RENDERING SYSTEMS

Methods and systems are provided for using temporal supersampling to increase a displayed resolution associated with peripheral region of a foveated rendering view. A method for enabling reconstitution of higher resolution pixels from a low resolution sampling region for fragment data is provided. The method includes an operation for receiving a fragment from a rasterizer of a GPU and for applying temporal supersampling to the fragment with the low resolution sampling region over a plurality of prior frames to obtain a plurality of color values. The method further includes an operation for reconstituting a plurality of high resolution pixels in a buffer that is based on the plurality of color values obtained via the temporal supersampling. Moreover, the method includes an operation for sending the plurality of high resolution pixels for display. 1. A method , comprising:generating a plurality of frames in a graphics pipeline when executing an application;rendering an object for a low resolution pixel for the plurality of frames by sampling the low resolution pixel at a plurality of unique sampling locations over the plurality of frames, wherein the low resolution pixel includes a subset of pixels taken from a plurality of native pixels of a display;storing in a temporal buffer a plurality of sampled color values and a plurality of locations on a display corresponding to the plurality of unique sampling locations for the plurality of frames, wherein the plurality of sampled color values and the plurality of locations are determined during the rendering of the low resolution pixel; andreprojecting the plurality of sampled color values to the subset of pixels at high resolution for a current frame.2. The method of claim 1 , further comprising:rendering at high resolution a plurality of native pixels in a foveal region for the plurality of frames,wherein attention of a user is directed to the foveal region,wherein the low resolution pixel is located in a peripheral ...

Foveal adaptation of particles and simulation models in a foveated rendering system

A method for implementing a graphics pipeline. The method includes generating a system of particles creating an effect in a virtual scene, the system of particles comprising a plurality of particle geometries. The method includes determining a subsystem of particles from the system of particles, the subsystem of particles comprising a subset of particle geometries taken from the plurality of particle geometries. The method includes determining a foveal region when rendering an image of the virtual scene, wherein the foveal region corresponds to where an attention of a user is directed. The method includes determining that at least one portion of the effect is located in the peripheral region for the image. The method includes rendering the subsystem of particles to generate the effect.

ADAPTIVE MESH SKINNING IN A FOVEATED RENDERING SYSTEM

A method for implementing a graphics pipeline. The method includes generating a plurality of bones for an object defining positioning relationships between the bones. The method includes determining a subsystem of bones from the plurality of bones for the object. The method includes determining a foveal region when rendering an image of the virtual scene including the object, wherein the foveal region corresponds to where an attention of a user is directed. The method includes determining that at least one portion of the object is located in a peripheral region for the image. The method includes animating the object by applying a transformation to the subsystem of bones.

Polystyrene sulfonate polymer tablets, their preparation and use

The present invention provides tablets containing at least about 70% of polystyrene sulfonate polymer, binder and moisture. The invention further relates to methods of treating medical conditions including antibiotic-associated diarrhea such as that caused by Chlostridium difficile, comprising administration of the tablets to a subject in need thereof. Furthermore, pharmaceutical blends and methods of preparing the tablets are disclosed.

Adaptive mesh skinning in a foveated rendering system

A method for implementing a graphics pipeline. The method includes generating a plurality of bones for an object defining positioning relationships between the bones. The method includes determining a subsystem of bones from the plurality of bones for the object. The method includes determining a foveal region when rendering an image of the virtual scene including the object, wherein the foveal region corresponds to where an attention of a user is directed. The method includes determining that at least one portion of the object is located in a peripheral region for the image. The method includes animating the object by applying a transformation to the subsystem of bones.

Pharmaceutical formulations of tropomyosin related kinase (TRK) inhibitors

Pharmaceutical formulations with a tropomyosin-related kinase inhibitor (“Trk inhibitor”) are disclosed. The pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine in microcrystalline suspension formulations in its monohydrate form, which shows improved characteristics over the anhydrate form, and in extended release formulations. The extended release pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine-loaded microspheres.

PHARMACEUTICAL FORMULATIONS OF TROPOMYOSIN RELATED KINASE (TRK) INHIBITORS

Pharmaceutical formulations with a tropomyosin-related kinase inhibitor (“Trk inhibitor”) are disclosed. The pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine in microcrystalline suspension formulations in its monohydrate form, which shows improved characteristics over the anhydrate form, and in extended release formulations. The extended release pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine-loaded microspheres.

Optimized shadows in a foveated rendering system

A method for implementing a graphics pipeline. The method includes building a first shadow map of high resolution, and building a second shadow map based on the first shadow map of lower resolution. The method includes determining a light source affecting a virtual scene, and projecting geometries of objects of an image of the virtual scene onto a plurality of pixels of a display from a first point-of-view. The method includes determining a foveal region when rendering the image, wherein the foveal region corresponds to where an attention of a user is directed. The method includes determining a first set of geometries is drawn to a first pixel, determining the first set of geometries is in shadow based on the light source, and determining the first set of geometries is outside of the foveal region. The method includes rendering the first set of geometries using the second shadow map.

PHARMACEUTICAL FORMULATIONS OF TROPOMYOSIN RELATED KINASE (TRK) INHIBITORS

Pharmaceutical formulations with a tropomyosin-related kinase inhibitor (“Trk inhibitor”) are disclosed. The pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5b-]pyridin-2-amine in microcrystalline suspension formulations in its monohydrate form, which shows improved characteristics over the anhydrate form, and in extended release formulations. The extended release pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine-loaded microspheres.

OPTIMIZED SHADOWS IN A FOVEATED RENDERING SYSTEM

A method for implementing a graphics pipeline. The method includes building a first shadow map of high resolution, and building a second shadow map based on the first shadow map of lower resolution. The method includes determining a light source affecting a virtual scene, and projecting geometries of objects of an image of the virtual scene onto a plurality of pixels of a display from a first point-of-view. The method includes determining a foveal region when rendering the image, wherein the foveal region corresponds to where an attention of a user is directed. The method includes determining a first set of geometries is drawn to a first pixel, determining the first set of geometries is in shadow based on the light source, and determining the first set of geometries is outside of the foveal region. The method includes rendering the first set of geometries using the second shadow map. 1. A method for implementing a graphics pipeline , comprising:building a first shadow map of high resolution;building a second shadow map based on the first shadow map, wherein the second shadow map has a lower resolution than the first shadow map;determining a light source affecting a virtual scene;projecting geometries of objects of an image of the virtual scene onto a plurality of pixels of a display from a first point-of-view;determining a first set of geometries is drawn to a first pixel;determining the first set of geometries is in shadow based on the light source;determining a foveal region when rendering an image of the virtual scene, wherein the foveal region corresponds to where an attention of a user is directed;determining the first set of geometries is outside of the foveal region; andrendering the first set of geometries for the first pixel using the second shadow map.2. The method of claim 1 , further comprising:determining that a second set of geometries is drawn to a second pixel;determining the second set of geometries is inside the foveal region; andrendering the ...

Temporal Supersampling for Foveated Rendering Systems

Methods and systems are provided for using temporal supersampling to increase a displayed resolution associated with peripheral region of a foveated rendering view. A method for enabling reconstitution of higher resolution pixels from a low resolution sampling region for fragment data is provided. The method includes an operation for receiving a fragment from a rasterizer of a GPU and for applying temporal supersampling to the fragment with the low resolution sampling region over a plurality of prior frames to obtain a plurality of color values. The method further includes an operation for reconstituting a plurality of high resolution pixels in a buffer that is based on the plurality of color values obtained via the temporal supersampling. Moreover, the method includes an operation for sending the plurality of high resolution pixels for display. 1. A method for drawing higher resolution pixels from a low resolution sampling region , comprising:receiving a fragment from a rasterizer;applying temporal supersampling to the fragment with the low resolution sampling region over a plurality of prior frames for obtaining a plurality color values;reconstituting a plurality of high resolution pixels in a buffer based on the plurality of color values obtained via the temporal supersampling; andsending, from the buffer, the plurality of high resolution pixels for presentation on a display.2. The method of claim 1 , wherein the temporal supersampling includes sampling at one location within the low resolution sampling region for each of the plurality of prior frames.3. The method of claim 1 , wherein the temporal supersampling includes sampling locations for the low resolution sampling region as determined by pixel reprojection.4. The method of claim 1 , wherein the temporal supersampling includes sampling locations for the low resolution sampling region as determined by jitter.5. The method of claim 1 , wherein the plurality of high resolution pixels is greater in number than ...

Temporal Supersampling for Foveated Rendering Systems

Methods and systems are provided for using temporal supersampling to increase a displayed resolution associated with peripheral region of a foveated rendering view. A method for enabling reconstitution of higher resolution pixels from a low resolution sampling region for fragment data is provided. The method includes an operation for receiving a fragment from a rasterizer of a GPU and for applying temporal supersampling to the fragment with the low resolution sampling region over a plurality of prior frames to obtain a plurality of color values. The method further includes an operation for reconstituting a plurality of high resolution pixels in a buffer that is based on the plurality of color values obtained via the temporal supersampling. Moreover, the method includes an operation for sending the plurality of high resolution pixels for display.

OPTIMIZED SHADOWS IN A FOVEATED RENDERING SYSTEM

A method for implementing a graphics pipeline. The method includes building a first shadow map of high resolution, and building a second shadow map based on the first shadow map of lower resolution. The method includes determining a light source affecting a virtual scene, and projecting geometries of objects of an image of the virtual scene onto a plurality of pixels of a display from a first point-of-view. The method includes determining a foveal region when rendering the image, wherein the foveal region corresponds to where an attention of a user is directed. The method includes determining a first set of geometries is drawn to a first pixel, determining the first set of geometries is in shadow based on the light source, and determining the first set of geometries is outside of the foveal region. The method includes rendering the first set of geometries using the second shadow map.

FOVEAL ADAPTATION OF PARTICLES AND SIMULATION MODELS IN A FOVEATED RENDERING SYSTEM

A method for implementing a graphics pipeline. The method includes generating a system of particles creating an effect in a virtual scene, the system of particles comprising a plurality of particle geometries. The method includes determining a subsystem of particles from the system of particles, the subsystem of particles comprising a subset of particle geometries taken from the plurality of particle geometries. The method includes determining a foveal region when rendering an image of the virtual scene, wherein the foveal region corresponds to where an attention of a user is directed. The method includes determining that at least one portion of the effect is located in the peripheral region for the image. The method includes rendering the subsystem of particles to generate the effect. 1. A method for implementing a graphics pipeline , comprising:generating a system of particles creating an effect in a virtual scene, the system of particles comprising a plurality of particle geometries;determining a subsystem of particles from the system of particles, the subsystem of particles comprising a subset of particle geometries taken from the plurality of particle geometries;determining a foveal region when rendering an image of the virtual scene, wherein the foveal region corresponds to where an attention of a user is directed;determining that at least one portion of the effect is located in the peripheral region for the image; andrendering the subsystem of particles to generate the effect.2. The method of claim 1 , wherein the determining a subsystem of particles comprises:inputting a plurality of particle vertices into the graphics pipeline;generating the plurality of particle geometries from the plurality of particle vertices;simulating the effect using the plurality of particle geometries;sampling the plurality of particles to generate the subsystem of particles; andrendering the subset of particle geometries corresponding to the subsystem of particles.3. The method of ...

OPTIMIZED DEFERRED LIGHTING IN A FOVEATED RENDERING SYSTEM

A method for implementing a graphics pipeline. The method includes determining a plurality of light sources affecting a virtual scene. Geometries of objects of an image of the scene is projected onto a plurality of pixels of a display from a first point-of-view. The pixels are partitioned into a plurality of tiles. A foveal region of highest resolution is defined for the image as displayed, wherein a first subset of pixels is assigned to the foveal region, and wherein a second subset of pixels is assigned to a peripheral region that is outside of the foveal region. A first set of light sources is determined from the plurality of light sources that affect one or more objects displayed in a first tile that is in the peripheral region. At least two light sources from the first set is clustered into a first aggregated light source affecting the first tile when rendering the image in pixels of the first tile. 1. A method for implementing a graphics pipeline , comprising:determining a plurality of light sources affecting a virtual scene;projecting geometries of objects of an image of the scene onto a plurality of pixels of a display from a first point-of-view;partitioning a plurality of pixels of the display into a plurality of tiles;defining a foveal region of highest resolution for the image as displayed, wherein a first subset of pixels is assigned to the foveal region, and wherein a second subset of pixels is assigned to a peripheral region that is outside of the foveal region;determining a first set of light sources from the plurality of light sources that affect one or more objects displayed in a first tile that is in the peripheral region; andclustering at least two light sources from the first set into a first aggregated light source affecting the first tile when rendering the image in pixels of the first tile.2. The method of claim 1 , further comprising:generating a plurality of clusters of light sources from the plurality of light sources using a nearest ...

Method for producing high concentration carbon dioxide product

A method for producing carbon dioxide in a high concentration suitable for direct usage or more facile further purification wherein microbial growth and fermentation of one or more carbonaceous materials are carried out with the use of defined high concentration oxidant fluid which is provided to a fermentation broth to provide oxygen in a defined limited amount.

Optimized shadows in a foveated rendering system

A method for implementing a graphics pipeline. The method includes building a first shadow map of high resolution, and building a second shadow map based on the first shadow map of lower resolution. The method includes determining a light source affecting a virtual scene, and projecting geometries of objects of an image of the virtual scene onto a plurality of pixels of a display from a first point-of-view. The method includes determining a foveal region when rendering the image, wherein the foveal region corresponds to where an attention of a user is directed. The method includes determining a first set of geometries is drawn to a first pixel, determining the first set of geometries is in shadow based on the light source, and determining the first set of geometries is outside of the foveal region. The method includes rendering the first set of geometries using the second shadow map.

Glucopyranosyl Lipid A and Allergen Formulations For Sublingual Administration

The present application relates to compositions and methods for treating allergy, e.g., peanut allergy, in patients. The methods involve administering glucopyranosyl lipid adjuvant (GLA) and peanut allergen(s) to the patient via a sublingual route.

SYSTEM AND METHOD FOR IMPROVED COMPUTER DRUG DESIGN

A system and method for computer-aided drug design is less restricted by accuracy of calculated ligand-receptor binding affinity, better copes with the flexibility of ligands and its effect on binding affinity, and limits the generation of undesirable compounds and the likelihood of biasing results with assumptions made in development.

Foveal adaptation of temporal anti-aliasing

Methods and systems are provided for enabling foveal adaption of temporal anti-aliasing within a foveated rendering presentation. A method for rendering a multi-resolution scene with anti-aliasing within a head mounted display (HMD) is provided. The method includes an operation for rendering a scene that includes a series of video frames. The method also includes operations for applying anti-aliasing to a first region of the scene using a first jitter offset and applying anti-aliasing to a second region of the scene using a second jitter offset. Further, the method provides for generating a foveated scene that includes the first region and the second region and for sending the foveated scene to be displayed on a display associated with the HMD, wherein the first region is associated with a higher resolution than the second scene and the first jitter offset is smaller than the second jitter offset, according to certain embodiments.

Foveal Adaptation of Temporal Anti-Aliasing

Methods and systems are provided for enabling foveal adaption of temporal anti-aliasing within a foveated rendering presentation. A method for rendering a multi-resolution scene with anti-aliasing within a head mounted display (HMD) is provided. The method includes an operation for rendering a scene that includes a series of video frames. The method also includes operations for applying anti-aliasing to a first region of the scene using a first jitter offset and applying anti-aliasing to a second region of the scene using a second jitter offset. Further, the method provides for generating a foveated scene that includes the first region and the second region and for sending the foveated scene to be displayed on a display associated with the HMD, wherein the first region is associated with a higher resolution than the second scene and the first jitter offset is smaller than the second jitter offset, according to certain embodiments. 1. A method for rendering a multi-resolution scene with temporal anti-aliasing within a head mounted display (HMD) , comprising:rendering, using a graphics processing unit, a scene including a series of video frames;applying anti-aliasing to a first region of the scene using a first jitter offset;applying anti-aliasing to a second region of the scene using a second jitter offset;generating a foveated scene that includes the first region of the scene and the second region of the scene; andsending the foveated scene for display on a display associated with the HMD, wherein the first region is associated with a higher resolution than the second region, and the first jitter offset is smaller than the second jitter offset.2. The method of claim 1 , further comprising:tracking a gaze of a user of the HMD; andwherein said generating the foveated scene includes dynamically placing the first region within the display associated with the HMD in accordance with said tracking the gaze of the user.3. The method of claim 1 , further comprising:applying ...

OPTIMIZED DEFERRED LIGHTING IN A FOVEATED RENDERING SYSTEM

A method for implementing a graphics pipeline. The method includes determining a plurality of light sources affecting a virtual scene. Geometries of objects of an image of the scene is projected onto a plurality of pixels of a display from a first point-of-view. The pixels are partitioned into a plurality of tiles. A foveal region of highest resolution is defined for the image as displayed, wherein a first subset of pixels is assigned to the foveal region, and wherein a second subset of pixels is assigned to a peripheral region that is outside of the foveal region. A first set of light sources is determined from the plurality of light sources that affect one or more objects displayed in a first tile that is in the peripheral region. At least two light sources from the first set is clustered into a first aggregated light source affecting the first tile when rendering the image in pixels of the first tile. 1. A method for implementing a graphics pipeline , comprising:determining a plurality of light sources affecting a virtual scene, wherein each of the plurality of light sources is a virtual light source used when rendering an image of the virtual scene in the graphics pipeline;projecting geometries of objects of the image of the virtual scene onto a plurality of pixels from a first point-of-view;determining that a geometry is projected onto a pixel that is in a peripheral region that is outside a foveal region of highest resolution;clustering a plurality of light sources affecting the geometry into an aggregated light source when rendering the geometry through the graphics pipeline.2. The method of claim 1 , wherein the geometry is a primitive of an object.3. The method of claim 1 , wherein the geometry is a pixel sized fragment of an object.4. The method of claim 1 , further comprising:determining that a second geometry is projected onto a second pixel that is in the foveal region from the first point-of-view; andrendering the second geometry through the graphics ...

Temporal supersampling for foveated rendering systems

Methods and systems are provided for using temporal supersampling to increase a displayed resolution associated with peripheral region of a foveated rendering view. A method for enabling reconstitution of higher resolution pixels from a low resolution sampling region for fragment data is provided. The method includes an operation for receiving a fragment from a rasterizer of a GPU and for applying temporal supersampling to the fragment with the low resolution sampling region over a plurality of prior frames to obtain a plurality of color values. The method further includes an operation for reconstituting a plurality of high resolution pixels in a buffer that is based on the plurality of color values obtained via the temporal supersampling. Moreover, the method includes an operation for sending the plurality of high resolution pixels for display.

Temporal supersampling for foveated rendering systems

Methods and systems are provided for using temporal supersampling to increase a displayed resolution associated with peripheral region of a foveated rendering view. A method for enabling reconstitution of higher resolution pixels from a low resolution sampling region for fragment data is provided. The method includes an operation for receiving a fragment from a rasterizer of a GPU and for applying temporal supersampling to the fragment with the low resolution sampling region over a plurality of prior frames to obtain a plurality of color values. The method further includes an operation for reconstituting a plurality of high resolution pixels in a buffer that is based on the plurality of color values obtained via the temporal supersampling. Moreover, the method includes an operation for sending the plurality of high resolution pixels for display.

FOVEAL ADAPTATION OF PARTICLES AND SIMULATION MODELS IN A FOVEATED RENDERING SYSTEM

A method for implementing a graphics pipeline. The method includes generating a system of particles creating an effect in a virtual scene, the system of particles comprising a plurality of particle geometries. The method includes determining a subsystem of particles from the system of particles, the subsystem of particles comprising a subset of particle geometries taken from the plurality of particle geometries. The method includes determining a foveal region when rendering an image of the virtual scene, wherein the foveal region corresponds to where an attention of a user is directed. The method includes determining that at least one portion of the effect is located in the peripheral region for the image. The method includes rendering the subsystem of particles to generate the effect. 1. A method for implementing a graphics pipeline , comprising:tracking an eye of a user viewing a virtual scene using a head mounted display;determining a foveal region when rendering an image of the virtual scene based on a direction of the eye of the user towards the virtual scene;rendering a first portion of an effect for the virtual scene using a system of particles, the first portion of the effect being located in the foveal region, the effect being partially defined by the system of particles comprising a plurality of particle geometries; andrendering a second portion of the effect for the virtual scene using a subsystem of particles from the system of particles, the second portion of the effect being located in a peripheral region outside of the foveal region, the subsystem of particles comprising a subset of particle geometries taken from the plurality of particle geometries.2. The method of claim 1 , further comprising:defining a bounding box for the system of particles; anddetermining that a portion of the bounding box is in the peripheral region.3. The method of claim 1 , further comprising:inputting a plurality of particle vertices into the graphics pipeline;generating the ...

SYSTEM AND METHOD TO ESTABLISH AND USE CREDENTIALS FOR A COMMON LIGHTWEIGHT IDENTITY THROUGH DIGITAL CERTIFICATES

A system and method for authentication of a user using “lightweight” identities. The system and method provides for establishment of user credentials for a particular electronic mail address by an identity server through the recordation of a mail token and private token after receiving a request for credentials from the user. The identity server sends a private token to the user and sends a verification message to the user containing a specific link to the identity server for verification of the user along with the mail token, and then can verify the user by confirming that a mail token and private token recorded by the identity server match a mail token and a private token received from the user. After the verification process is successful, the identity server issues credentials that consist of a certificate either with or without a private key to the user which serves as an authenticated, unique, lightweight identity that a user can assume to access various services. 1. A method for establishing user credentials of a service on a computer network by an identity server , comprising the steps of:receiving from a requesting software application a request for the issuance of new credentials for an electronic mail address;generating a mail token;recording the mail token and a private token;sending the private token to the requesting software application;sending a verification message to said electronic mail address including a verification link for credentials and the mail token generated in said generating step;receiving a request for verification from said electronic mail address through said verification link including a mail token and a private token transmitted by the requesting software application;verifying the request for verification including verifying that the mail token and the private token received from said requesting software application match the mail token and the private token recorded in said recording step; andissuing and sending the new ...

PHARMACEUTICAL FORMULATIONS OF TROPOMYOSIN RELATED KINASE (TRK) INHIBITORS

Pharmaceutical formulations with a tropomyosin-related kinase inhibitor (“Trk inhibitor”) are disclosed. The pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine in microcrystalline suspension formulations in its monohydrate form, which shows improved characteristics over the anhydrate form, and in extended release formulations. The extended release pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine-loaded microspheres. 1. A crystalline form of 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4 ,5-b]pyridin-2-amine , wherein the x-ray powder diffraction pattern contains the following 26 peaks measured using CuKradiation: 3.6 , 7.1 , 8.9 , 10.4 , 10.7 , 12.4 , 12.7 and 14.3.2. A pharmaceutical formulation comprising the crystalline form of 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4 claim 1 ,5-b]pyridin-2-amine according to and a pharmaceutically acceptable excipient.5. The pharmaceutical formulation according to claim 4 , wherein the pharmaceutically acceptable excipient comprises a diluent.6. The pharmaceutical formulation according to claim 5 , wherein the diluent is selected from: malitol claim 5 , sunflower oil claim 5 , ammonium alginate claim 5 , calcium carbonate claim 5 , calcium lactate claim 5 , calcium phosphatedibasic anhydrous claim 5 , dibasic dihydrate claim 5 , tribasic claim 5 , calcium silicate claim 5 , calcium sulfate claim 5 , cellulose (powdered claim 5 , silicified microcrystalline) claim 5 , cellulose acetate claim 5 , compressible sugar claim 5 , confectioner's sugar claim 5 , corn starch and pregelatinized starch claim 5 , dextrates claim 5 , dextrin claim 5 , dextrose claim 5 , erythritol claim 5 , ethylcellulose claim 5 , fructose claim 5 , fumaric acid claim 5 , glyceryl ...

SOUND SOURCE RENDERING IN VIRTUAL ENVIRONMENT

Embodiments are directed to sound source rendering in a virtual reality (VR) system that executes an immersive virtual environment including at least one virtual sound source. A motion sensor to produces a measurement of a motion of the user, and an imaging sensor is used to produce an indication of at least one physical feature of the user relevant to sound perception. A sound rendering engine determines and applies a head-related transfer function (HRTF) based on the at least one physical feature of the user, and effects a source direction of sound from the at least one virtual sound source according to a frame of reference of the user based on the motion of the user. 1. A system for sound source rendering in a virtual reality (VR) system , the system comprising:a modeling engine to execute an immersive virtual environment (VE) that includes at least one virtual sound source;a motion assessor to read an output of a motion sensor to produce a measurement of a motion of the user during execution of the VE;a physical feature assessor to read an output of an imaging sensor and produce an indication of at least one physical feature of the user relevant to sound perception by the user, wherein the physical feature assessor is to read an output of an imaging sensor and produce an indication of at least one physical feature of the user during execution of the VE;a sound rendering engine to determine and apply a head-related transfer function (HRTF) based on the at least one physical feature of the user, and to effect a source direction of sound from the at least one virtual sound source according to a frame of reference of the user based on the motion of the user during execution of the VE; anda sound output device to produce a user-perceptible sound from the virtual sound source based on an output of the sound rendering engine during execution of the VE, the sound having directional properties based on the HRTF and source direction.2. The system of claim 1 , further ...

PHARMACEUTICAL COMPOSITIONS COMPRISING VENGLUSTAT

The present disclosure relates to pharmaceutical compositions, including dosage forms, such as tablets or capsules, comprising venglustat, in free base, or pharmaceutically acceptable salt form, a diluent/filler and a lubricant, optionally in combination with one or more additional therapeutic agents, to processes for manufacture thereof, and to methods of use in the treatment or prevention of disease. 2. The process according to claim 1 , wherein the venglustat is venglustat malate.3. The process according to claim 1 , wherein steps (i) claim 1 , (j) claim 1 , and/or (k) are repeated for additional excipients added in step (h) before proceeding to steps (l) claim 1 , (m) claim 1 , or (n).4. The process according to claim 1 , wherein a lubricant is combined with the venglustat and the diluent/filler in step (b).5. The process according to claim 1 , wherein the composition is a solid tablet claim 1 , and wherein sodium stearyl fumarate is added as a first lubricant in combining step (b).6. The process according to claim 1 , wherein the composition is a solid tablet claim 1 , and wherein magnesium stearate is added as a second lubricant which is added as the final excipient added before final mixing and compression to form the tablet.7. The process according to claim 1 , wherein the diluent/filler is mannitol claim 1 , and the disintegrant is crospovidone claim 1 , and the binder is hydroxypropyl cellulose claim 1 , and the lubricant is sodium stearyl fumarate and/or magnesium stearate claim 1 , and the glidant is silica.8. The process according to claim 1 , wherein the process comprises the following steps:(a) sieving one or more ingredients, for example, all ingredients, or only some ingredients (e.g., sieving half of the amount of microcrystalline cellulose, and/or silica), and lubricant (magnesium stearate and/or sodium stearyl fumarate));(b) combining venglustat malate with microcrystalline cellulose (a first portion), sucralose (if any), flavor (if any), and ...

OPTICAL PROBE, RAMAN SPECTROSCOPY SYSTEM, AND METHOD OF USING THE SAME

Provided is an optical probe, and a Raman spectroscopy system using such, including excitation and detection optics coupled to a sampling optics via a beam splitter, in confocal arrangement with a sample focal plane of the sampling optics. The detection optics is arranged to receive Raman signal from the sample focal plane and direct it onto a tip of a detection optical fiber. The optical probe may further include a positioning device mechanically coupled to the sampling optics and configured to control a position of the sample focal plane. In the Raman spectroscopy system a light source is coupled to the excitation optics via an excitation optical fiber, and a spectrometer is coupled to a detection optics via a detection optical fiber. Provided is further a method for measuring Raman signal depth profile in a sample, wherein sample's Raman spectra is measured and stored at different focal plane positions. 1. An optical probe for Raman spectroscopy system , comprising an excitation optics and a detection optics optically coupled to a sampling optics via a beam splitter and in confocal arrangement with a sample focal plane of the sampling optics , wherein the sampling optics and the detection optics are arranged to receive a Raman signal from the sample focal plane and direct it onto a tip of a detection optical fiber.2. The optical probe as in claim 1 , wherein the excitation optics is configured to receive an excitation optical fiber claim 1 , wherein the excitation optical fiber is an optical fiber configured to transmit excitation light from a light source.3. The optical probe as in claim 1 , wherein the excitation optics comprises at least one of a first collimator claim 1 , a second collimator.4. The optical probe as in claim 2 , wherein the tip of the excitation optical fiber is positioned at the focus of the excitation optics.56-. (canceled)7. The optical probe as in claim 2 , wherein the excitation optics and the sampling optics are arranged to direct light ...

METHOD AND SYSTEM FOR MULTI-MODAL IMAGING OF TISSUE

There is provided a method for multi-modal imaging of tissue. The method includes: providing a fiber probe over a target area of the tissue, the fiber probe including a plurality of source fiber channels, a plurality of detector fiber channels and a plurality of fiducial marker channels, the plurality of source fiber channels, the plurality of detector fiber channels and the plurality of fiducial marker channels having a predetermined spatial arrangement in the fiber probe; directing light through each of the plurality of source fiber channels of the fiber probe to the target area in succession for performing optical imaging of the target area; obtaining optical imaging data of the target area based on attenuated light from the target area detected through the plurality of detector fiber channels due to said light directed to the target area; obtaining MRI data of the target area based on a MRI of the target area; and coregistering the optical imaging data and the MRI data based on a plurality of fiducial features captured in the MRI data corresponding to the plurality of fiducial marker channels of the fiber probe. There is also provide a corresponding system for multi-modal imaging of tissue. 1. A method for multi-modal imaging of tissue , the method comprising:providing a fiber probe over a target area of the tissue, the fiber probe comprising a plurality of source fiber channels, a plurality of detector fiber channels and a plurality of fiducial marker channels, the plurality of source fiber channels, the plurality of detector fiber channels and the plurality of fiducial marker channels having a predetermined spatial arrangement in the fiber probe;directing light through each of the plurality of source fiber channels of the fiber probe to the target area in succession for performing optical imaging of the target area;obtaining optical imaging data of the target area based on attenuated light from the target area detected through the plurality of detector fiber ...

Small molecule parg inhibitors and methods of use thereof

The present disclosure provides methods of inhibiting PARG in cancer cells, including methods comprising administering a PARG inhibitor that modulates position Tyr795 in PARG. Also provided herein are methods of treating and/or preventing cancer comprising administering a PARG inhibitor. In some embodiments, the PARG inhibitors are of the formula: wherein the variables are defined herein.

Small molecule parg inhibitors and methods of use thereof

Optimized deferred lighting and foveal adaptation of particles and simulation models in a foveated rendering system

Acetaminophen sustained-release formulation

An orally administrable sustained-release dosage form includes particles of an active pharmaceutical ingredient which is coated with a polymeric material that is water-insoluble, but water-permeable and water-swellable, so that the sustained-release dosage form provides controlled release which is independent of certain variable physiological factors such as pH. In accordance with one aspect of the invention, the active pharmaceutical ingredient is acetaminophen and the coated acetaminophen particles are combined with uncoated acetaminophen particles to provide a combination immediate-release/sustained-release dosage form. In accordance with another aspect of the invention, the active pharmaceutical ingredient is coated with a methacrylate ester copolymer, and the coated particles are combined with uncoated particles of an active pharmaceutical ingredient to provide a combination immediate-release/sustained-release dosage form, wherein the sustained-release component provides a release rate which is substantially independent of physiological factors such as pH. The final orally administrable dosage form can appear as compressed tablets, capsules or pouches.

PULPATION PROCESS

Polystyrene sulfonate polymer tablets, their preparation and use

System and method to establish and use credentials for a common lightweight identity through digital certificates

A system and method for authentication of a user using “lightweight” identities. The system and method provides for establishment of user credentials for a particular electronic mail address by an identity server through the recordation of a mail token and private token after receiving a request for credentials from the user. The identity server sends a private token to the user and sends a verification message to the user containing a specific link to the identity server for verification of the user along with the mail token, and then can verify the user by confirming that a mail token and private token recorded by the identity server match a mail token and a private token received from the user. After the verification process is successful, the identity server issues credentials that consist of a certificate either with or without a private key to the user which serves as an authenticated, unique, lightweight identity that a user can assume to access various services.

Small molecule parg inhibitors and methods of use thereof

The present disclosure provides methods of inhibiting PARG in cancer cells, including methods comprising administering a PARG inhibitor that modulates position Tyr795 in PARG. Also provided herein are methods of treating and/or preventing cancer comprising administering a PARG inhibitor. In some embodiments, the PARG inhibitors are of the formula: wherein the variables are defined herein.

System and method for improved computer drug design

A system and method for computer-aided drug design employs adaptive sampling and iterative fitting of mult-atomic subunits. The iterative fitting is performed by successive perturbation of the location of the multi-atomic subunits in directions that reduces potential energy.

Black liquor treatment

ABSTRACT OF THE DISCLOSURE Concentrated black liquor formed in a kraft pulp mill process is treated to effect exothermal oxidation of black liquor solids, so as to heat the concentrated black liquor and consume a proportion of the black liquor solids. Such procedure eliminates the need to use steam to preheat black liquor and decreases the overall heating value of the concentrated black liquor, allowing an increased black liquor recovery boiler capacity to be achieved.

Pharmaceutical formulations of tropomyosin related kinase (trk) inhibitors

Pharmaceutical formulations with a tropomyosin-related kinase inhibitor (”Trk inhibitor”) are disclosed. The pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine in microcrystalline suspension formulations in its monohydrate form, which shows improved characteristics over the anhydrate form, and in extended release formulations. The extended release pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine-loaded microspheres.

Systems and methods for an electronic presentation controller

The present disclosure relates to an electronic presentation controller that allows an orator to select features that the orator may use during a presentation, and disable other features of the electronic presentation controller. An electronic presentation controller according to the present disclosure may include a wide range of advanced features, that may be activated or deactivated selectively, thus minimizing the potential for unwanted and potentially embarrassing interruptions during presentation by disabling functions that are not being used by the orator.

Acetaminophen sustained-release formulation

An orally administrable sustained-release dosage form includes particles of an active pharmaceutical ingredient which is coated with a polymeric material that is water-insoluble, but water-permeable and water-swellable, so that the sustained-release dosage form provides controlled release which is independent of certain variable physiological factors such as pH. In accordance with one aspect of the invention, the active pharmaceutical ingredient is acetaminophen and the coated acetaminophen particles are combined with uncoated acetaminophen particles to provide a combination immediate-release/sustained-release dosage form. In accordance with another aspect of the invention, the active pharmaceutical ingredient is coated with a methacrylate ester copolymer, and the coated particles are combined with uncoated particles of an active pharmaceutical ingredient to provide a combination immediate-release/sustained-release dosage form, wherein the sustained-release component provides a release rate which is substantially independent of physiological factors such as pH. The final orally administrable dosage form can be appeared as compressed tablets, capsules or pouches.

Optical probe, raman spectroscopy system, and method of using the same

Provided is an optical probe, and a Raman spectroscopy system using such, including excitation and detection optics coupled to a sampling optics via a beam splitter, in confocal arrangement with a sample focal plane of the sampling optics. The detection optics is arranged to receive Raman signal from the sample focal plane and direct it onto a tip of a detection optical fiber. The optical probe may further include a positioning device mechanically coupled to the sampling optics and configured to control a position of the sample focal plane. In the Raman spectroscopy system a light source is coupled to the excitation optics via an excitation optical fiber, and a spectrometer is coupled to a detection optics via a detection optical fiber. Provided is further a method for measuring Raman signal depth profile in a sample, wherein sample's Raman spectra is measured and stored at different focal plane positions.

Method for producing high concentration carbon dioxide product

A method for producing carbon dioxide in a high concentration suitable for direct usage or more facile further purification wherein microbial growth and fermentation of one or more carbonaceous materials are carried out with the use of defined oxygen-enriched fluid.

Pharmaceutical compositions comprising venglustat

The present disclosure relates to pharmaceutical compositions, including dosage forms, such as tablets or capsules, comprising venglustat, in free base, or pharmaceutically acceptable salt form, a diluent/filler and a lubricant, optionally in combination with one or more additional therapeutic agents, to processes for manufacture thereof, and to methods of use in the treatment or prevention of disease.

Stat3 degraders and uses thereof

The present invention relates to STAT3 degraders, their liquid formulations, and methods of use thereof for treating cancer.

Small molecule parg inhibitors and methods of use thereof

The present disclosure provides methods of inhibiting PARG in cancer cells, including methods comprising administering a PARG inhibitor that modulates position Tyr795 in PARG. Also provided herein are methods of treating and/or preventing cancer comprising administering a PARG inhibitor. In some embodiments, the PARG inhibitors are of the formula: wherein the variables are defined herein.

Composiciones farmaceuticas que comprenden venglustat.

La presente divulgación se refiere a composiciones farmacéuticas, incluyendo formas de dosificación, tales como comprimidos o cápsulas, que comprenden venglustat, en forma de base libre, o sal farmacéuticamente aceptable, un diluyente/relleno y un lubricante, opcionalmente en combinación con uno o más agentes terapéuticos adicionales, a procesos para la fabricación de los mismos, y a métodos de uso en el tratamiento o prevención de enfermedades.

Foveal adaptation of temporal anti-aliasing

Methods and systems are provided for enabling foveal adaption of temporal anti-aliasing within a foveated rendering presentation. A method for rendering a multi-resolution scene with anti-aliasing within a head mounted display (HMD) is provided. The method includes an operation for rendering a scene that includes a series of video frames. The method also includes operations for applying anti-aliasing to a first region of the scene using a first jitter offset and applying anti-aliasing to a second region of the scene using a second jitter offset. Further, the method provides for generating a foveated scene that includes the first region and the second region and for sending the foveated scene to be displayed on a display associated with the HMD, wherein the first region is associated with a higher resolution than the second scene and the first jitter offset is smaller than the second jitter offset, according to certain embodiments.

Temporal supersampling for foveated rendering systems

Methods and systems are provided for using temporal supersampling to increase a displayed resolution associated with peripheral region of a foveated rendering view. A method for enabling reconstitution of higher resolution pixels from a low resolution sampling region for fragment data is provided. The method includes an operation for receiving a fragment from a rasterizer of a GPU and for applying temporal supersampling to the fragment with the low resolution sampling region over a plurality of prior frames to obtain a plurality of color values. The method further includes an operation for reconstituting a plurality of high resolution pixels in a buffer that is based on the plurality of color values obtained via the temporal supersampling. Moreover, the method includes an operation for sending the plurality of high resolution pixels for display.

Foveal adaptation of temporal anti-aliasing

Pharmaceutical compositions comprising venglustat

The present disclosure relates to pharmaceutical compositions, including dosage forms, such as tablets or capsules, comprising venglustat, in free base, or pharmaceutically acceptable salt form, a diluent/filler and a lubricant, optionally in combination with one or more additional therapeutic agents, to processes for manufacture thereof, and to methods of use in the treatment or prevention of disease.

Pharmaceutical formulations of tropomyosin related kinase (TRK) inhibitors

Pharmaceutical formulations with a tropomyosin-related kinase inhibitor (“Trk inhibitor”) are disclosed. The pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine in microcrystalline suspension formulations in its monohydrate form, which shows improved characteristics over the anhydrate form, and in extended release formulations. The extended release pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine-loaded microspheres.

Forma cristalina monohidratada, composição e formulações farmacêuticas de inibidores de cinases relacionadas à tropomiosina (trk)

lubrificante para alta temperatura para a indústria alimentícia. são divulgadas formulações farmacêuticas com um inibidor de cinase relacionada à tropomiosina ("inibidor de trk"). as formulações farmacêuticas compreendem a 3-(3-metóxi-4-((4-metoxibenzil)óxi)benzil)-6-(1-metil-1h-pirazol-4-il)-3h-imidazo[4,5-b]piridin-2-amina em formulações de suspensões microcristalinas em sua forma de mono-hidrato, que mostra características aperfeiçoadas sobre a forma sem hidrato, e em formulações de liberação prolongada. as formulações farmacêuticas de liberação prolongada compreendem microesferas carregadas com 3-(3-metóxi-4-((4-metoxibenzil)óxi)benzil)-6-(1-metil-1h-pirazol-4-il)-3h-imidazo[4,5-b]piridin-2-amina.

Graphics processing using dynamic resources

A system has a central processing unit (CPU) and a graphics processing unit (GPU) that includes one or more registers. The GPU can change a resource descriptor in one of the GPU's registers. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.

Method and system for multi-modal imaging of tissue

Pharmaceutical compositions comprising venglustat

The present disclosure relates to pharmaceutical compositions, including dosage forms, such as tablets or capsules, comprising venglustat, in free base, or pharmaceutically acceptable salt form, a diluent/filler and a lubricant, optionally in combination with one or more additional therapeutic agents, to processes for manufacture thereof, and to methods of use in the treatment or prevention of disease.

Foveal adaptation of temporal anti-aliasing

Methods and systems are provided for enabling foveal adaption of temporal anti-aliasing within a foveated rendering presentation. A method for rendering a multi-resolution scene with anti-aliasing within a head mounted display (HMD) is provided. The method includes an operation for rendering a scene that includes a series of video frames. The method also includes operations for applying anti-aliasing to a first region of the scene using a first jitter offset and applying anti-aliasing to a second region of the scene using a second jitter offset. Further, the method provides for generating a foveated scene that includes the first region and the second region and for sending the foveated scene to be displayed on a display associated with the HMD, wherein the first region is associated with a higher resolution than the second scene and the first jitter offset is smaller than the second jitter offset, according to certain embodiments.

Temporal supersampling for foveated rendering systems

Methods and systems are provided for using temporal supersampling to increase a displayed resolution associated with peripheral region of a foveated rendering view. A method for enabling reconstitution of higher resolution pixels from a low resolution sampling region for fragment data is provided. The method includes an operation for receiving a fragment from a rasterizer of a GPU and for applying temporal supersampling to the fragment with the low resolution sampling region over a plurality of prior frames to obtain a plurality of color values. The method further includes an operation for reconstituting a plurality of high resolution pixels in a buffer that is based on the plurality of color values obtained via the temporal supersampling. Moreover, the method includes an operation for sending the plurality of high resolution pixels for display.

Methods of treating cancer

The present invention relates to methods of treating solid cancers and hematological malignances using MDM2 degraders.

Stat3 degraders and uses thereof

The present invention relates to STAT3 degraders, their liquid formulations, and methods of use thereof for treating cancer.

Methods of treating cancer

The present invention relates to methods of treating solid cancers and hematological malignances using MDM2 degraders.

Method and system for multi-modal imaging of tissue

There is provided a method for multi-modal imaging of tissue. The method includes: providing a fiber probe over a target area of the tissue, the fiber probe including a plurality of source fiber channels, a plurality of detector fiber channels and a plurality of fiducial marker channels, the plurality of source fiber channels, the plurality of detector fiber channels and the plurality of fiducial marker channels having a predetermined spatial arrangement in the fiber probe; directing light through each of the plurality of source fiber channels of the fiber probe to the target area in succession for performing optical imaging of the target area; obtaining optical imaging data of the target area based on attenuated light from the target area detected through the plurality of detector fiber channels due to said light directed to the target area; obtaining MRI data of the target area based on a MRI of the target area; and coregistering the optical imaging data and the MRI data based on a plurality of fiducial features captured in the MRI data corresponding to the plurality of fiducial marker channels of the fiber probe. There is also provide a corresponding system for multi-modal imaging of tissue.

Method and system for multi-modal imaging of tissue

Method and system for multi-modal imaging of tissue

There is provided a method for multi-modal imaging of tissue. The method includes: providing a fiber probe over a target area of the tissue, the fiber probe including a plurality of source fiber channels, a plurality of detector fiber channels and a plurality of fiducial marker channels, the plurality of source fiber channels, the plurality of detector fiber channels and the plurality of fiducial marker channels having a predetermined spatial arrangement in the fiber probe; directing light through each of the plurality of source fiber channels of the fiber probe to the target area in succession for performing optical imaging of the target area; obtaining optical imaging data of the target area based on attenuated light from the target area detected through the plurality of detector fiber channels due to said light directed to the target area; obtaining MRI data of the target area based on a MRI of the target area; and coregistering the optical imaging data and the MRI data based on a plurality of fiducial features captured in the MRI data corresponding to the plurality of fiducial marker channels of the fiber probe. There is also provide a corresponding system for multi-modal imaging of tissue.

Stat3 degraders and uses thereof

The present invention relates to STAT3 degraders, their liquid formulations, and methods of use thereof for treating cancer.

Composiciones farmacéuticas que comprenden venglustat

La presente divulgación se refiere a composiciones farmacéuticas, incluyendo formas de dosificación, tales como comprimidos o cápsulas, que comprenden venglustat, en forma de base libre, o sal farmacéuticamente aceptable, un diluyente/relleno y un lubricante, opcionalmente en combinación con uno o más agentes terapéuticos adicionales, a procesos para la fabricación de los mismos, y a métodos de uso en el tratamiento o prevención de enfermedades.

Glucopyranosyl lipid a and peanut allergen formulations for sublingual administration

Temporal supersampling for foveated rendering systems

Metodos de tratamiento del cancer.

La presente invención se refiere a métodos para tratar cánceres sólidos y neoplasias malignas hematológicas usando degradadores de MDM2.

Degradadores de la proteina transductora de se?al y activadora de la transcripcion 3 (stat3) y usos de los mismos.

La presente invención se refiere a degradadores de STAT3, a sus formulaciones líquidas y a métodos de uso de los mismos para tratar el cáncer.

用於舌下施用的吡喃葡萄糖基脂質a和花生過敏原製劑

Stat3 degraders and uses thereof

The present invention relates to STAT3 degraders, their liquid formulations, and methods of use thereof for treating cancer.